Literature DB >> 21044669

Opsonophagocytic activity following a reduced dose 7-valent pneumococcal conjugate vaccine infant primary series and 23-valent pneumococcal polysaccharide vaccine at 12 months of age.

F M Russell1, J R Carapetis, R L Burton, J Lin, P V Licciardi, A Balloch, L Tikoduadua, L Waqatakirewa, Y B Cheung, M L K Tang, M H Nahm, E K Mulholland.   

Abstract

Opsonophagocytic activity (OPA) was measured following reduced infant doses of 7-valent pneumococcal conjugate vaccine (PCV-7) with or without 23-valent pneumococcal polysaccharide vaccine (PPV-23) at 12 months, and subsequent re-exposure to a small dose of pneumococcal polysaccharide antigens (mPPS) at 17 months. Fijian infants were randomized to receive 0, 1, 2, or 3 PCV-7 doses. Half received PPV-23 at 12 months and all received mPPS at 17 months. OPA was performed on up to 14 serotypes. Three and 2 PCV-7 doses resulted in similar OPA for most PCV-7 serotypes up to 9 months and for half of the serotypes at 12 months. A single dose improved OPA compared with the unvaccinated group. PPV-23 significantly improved OPA for all serotypes tested but in general, was associated with diminished responses following re-challenge. Copyright Â
© 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21044669      PMCID: PMC3011050          DOI: 10.1016/j.vaccine.2010.10.046

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

Review 2.  Serological criteria for evaluation and licensure of new pneumococcal conjugate vaccine formulations for use in infants.

Authors:  Luis Jódar; Jay Butler; George Carlone; Ron Dagan; David Goldblatt; Helena Käyhty; Keith Klugman; Brian Plikaytis; George Siber; Robert Kohberger; Ih Chang; Thomas Cherian
Journal:  Vaccine       Date:  2003-07-04       Impact factor: 3.641

3.  Immunogenicity of alternative regimens of the conjugated 7-valent pneumococcal vaccine: a randomized controlled trial.

Authors:  Noga Givon-Lavi; David Greenberg; Ron Dagan
Journal:  Pediatr Infect Dis J       Date:  2010-08       Impact factor: 2.129

4.  Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.

Authors:  N F Concepcion; C E Frasch
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

5.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

6.  Avidity, potency, and cross-reactivity of monoclonal antibodies to pneumococcal capsular polysaccharide serotype 6B.

Authors:  Y Sun; Y i Hwang; M H Nahm
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

7.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

8.  Protective efficacy of a second pneumococcal conjugate vaccine against pneumococcal acute otitis media in infants and children: randomized, controlled trial of a 7-valent pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine in 1666 children.

Authors:  Terhi Kilpi; Heidi Ahman; Jukka Jokinen; Kari S Lankinen; Arto Palmu; Heljä Savolainen; Marko Grönholm; Maija Leinonen; Tapani Hovi; Juhani Eskola; Helena Käyhty; Norman Bohidar; Jerald C Sadoff; P Helena Mäkelä
Journal:  Clin Infect Dis       Date:  2003-10-07       Impact factor: 9.079

9.  Efficiency of a pneumococcal opsonophagocytic killing assay improved by multiplexing and by coloring colonies.

Authors:  Kyung Hyo Kim; Jigui Yu; Moon H Nahm
Journal:  Clin Diagn Lab Immunol       Date:  2003-07

10.  Functional antibodies elicited by an 11-valent diphtheria-tetanus toxoid-conjugated pneumococcal vaccine.

Authors:  Taneli Puumalainen; Nina Ekström; Rose Zeta-Capeding; Jukka Ollgren; Kaisa Jousimies; Marilla Lucero; Hanna Nohynek; Helena Käyhty
Journal:  J Infect Dis       Date:  2003-05-09       Impact factor: 5.226

View more
  14 in total

1.  Pneumococcal polysaccharide vaccine at 12 months of age produces functional immune responses.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Robert L Burton; Jisheng Lin; Moon H Nahm; Edward K Mulholland; Mimi L K Tang
Journal:  J Allergy Clin Immunol       Date:  2012-02-02       Impact factor: 10.793

2.  Pneumococcal glycoconjugate vaccines produce antibody responses that strongly correlate with function.

Authors:  Paul V Licciardi; Anne Balloch; Fiona M Russell; Moon H Nahm; Kim Mulholland; Mimi L K Tang
Journal:  Nat Rev Drug Discov       Date:  2011-05       Impact factor: 84.694

Review 3.  New diagnostic criteria for common variable immune deficiency (CVID), which may assist with decisions to treat with intravenous or subcutaneous immunoglobulin.

Authors:  R Ameratunga; S-T Woon; D Gillis; W Koopmans; R Steele
Journal:  Clin Exp Immunol       Date:  2013-11       Impact factor: 4.330

4.  Serotype-specific avidity is achieved following a single dose of the 7-valent pneumococcal conjugate vaccine, and is enhanced by 23-valent pneumococcal polysaccharide booster at 12 months.

Authors:  F M Russell; A Balloch; P V Licciardi; J R Carapetis; L Tikoduadua; L Waqatakirewa; Y B Cheung; E K Mulholland; M L K Tang
Journal:  Vaccine       Date:  2011-05-01       Impact factor: 3.641

5.  Potential carrier priming effect in Australian infants after 7-valent pneumococcal conjugate vaccine introduction.

Authors:  Mohamed Tashani; Sanjay Jayasinghe; Zitta B Harboe; Harunor Rashid; Robert Booy
Journal:  World J Clin Pediatr       Date:  2016-08-08

6.  Pneumococcus with the "6E" cps Locus Produces Serotype 6B Capsular Polysaccharide.

Authors:  Robert L Burton; K Aaron Geno; Jamil S Saad; Moon H Nahm
Journal:  J Clin Microbiol       Date:  2016-01-27       Impact factor: 5.948

7.  Immunogenicity and safety of 23-valent pneumococcal polysaccharide vaccine as a booster dose in 12- to 18-month-old children primed with 3 doses of 7-valent pneumococcal conjugate vaccine.

Authors:  Usa Thisyakorn; Kulkanya Chokephaibulkit; Pope Kosalaraksa; Suwat Benjaponpitak; Chitsanu Pancharoen; Sunate Chuenkitmongkol
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

8.  Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.

Authors:  Teresa Jackowska; Justyna Pluta
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

9.  Characterization of 19A-like 19F pneumococcal isolates from Papua New Guinea and Fiji.

Authors:  E M Dunne; L Tikkanen; A Balloch; K Gould; M Yoannes; S Phuanukoonnon; P V Licciardi; F M Russell; E K Mulholland; C Satzke; J Hinds
Journal:  New Microbes New Infect       Date:  2015-07-04

10.  Pneumococcal polysaccharide abrogates conjugate-induced germinal center reaction and depletes antibody secreting cell pool, causing hyporesponsiveness.

Authors:  Stefania P Bjarnarson; Hreinn Benonisson; Giuseppe Del Giudice; Ingileif Jonsdottir
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.